The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.
T. Degenhardt
No relevant relationships to disclose
O. Gluz
Honoraria - Sanofi
H. H. Kreipe
No relevant relationships to disclose
R. E. Kates
No relevant relationships to disclose
C. Liedtke
Honoraria - Sanofi
Other Remuneration - Sanofi
S. Shak
Employment or Leadership Position - Genomic Health
M. R. Clemens
Honoraria - Amgen; Sanofi
Research Funding - Amgen; Sanofi
D. Augustin
No relevant relationships to disclose
U. Nitz
Honoraria - Amgen; Sanofi
Other Remuneration - Amgen; Sanofi
N. Harbeck
Honoraria - Amgen; Sanofi
Other Remuneration - Amgen; Sanofi